Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “promote” score reaffirmed by analysts at Bank of America in a observe issued to buyers on Wednesday, TipRanks reviews. They presently have a $8.00 price goal on the stock. Bank of America’s price goal suggests a possible draw back of 17.27% from the corporate’s earlier shut.
A number of different equities analysis analysts additionally just lately issued reviews on the stock. SunTrust Banks raised shares of Teva Pharmaceutical Industries from a “maintain” score to a “purchase” score and lifted their price goal for the stock from $11.00 to $16.00 in a analysis observe on Monday, June 1st. Zacks Funding Analysis raised shares of Teva Pharmaceutical Industries from a “promote” score to a “maintain” score and set a $13.00 price goal on the stock in a analysis observe on Wednesday, July 22nd. Barclays raised shares of Teva Pharmaceutical Industries from an “underweight” score to an “equal weight” score and lifted their price goal for the stock from $10.00 to $13.00 in a analysis observe on Thursday, August sixth. Cantor Fitzgerald reissued a “impartial” score on shares of Teva Pharmaceutical Industries in a analysis report on Friday, May eighth. Lastly, Goldman Sachs Group started protection on shares of Teva Pharmaceutical Industries in a analysis report on Monday, July 27th. They issued a “impartial” score and a $12.00 goal price for the corporate. 4 funding analysts have rated the stock with a promote score, eleven have assigned a maintain score and 5 have issued a purchase score to the corporate. The corporate has a median score of “Maintain” and a median price goal of $12.40.
Teva Pharmaceutical Industries stock opened at $9.67 on Wednesday. Teva Pharmaceutical Industries has a 12-month low of $6.25 and a 12-month excessive of $13.76. The corporate has a market capitalization of $10.52 billion, a price-to-earnings ratio of 4.19, a price-to-earnings-growth ratio of 0.73 and a beta of 1.58. The corporate has a debt-to-equity ratio of 1.66, a present ratio of 1.09 and a fast ratio of 0.72. The agency’s fifty day transferring common price is $11.52 and its 200 day transferring common price is $11.11.
Teva Pharmaceutical Industries (NYSE:TEVA) final launched its quarterly earnings outcomes on Wednesday, August fifth. The corporate reported $0.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.02. Teva Pharmaceutical Industries had a internet margin of 0.03% and a return on fairness of 17.88%. The agency had income of $3.87 billion for the quarter, in comparison with the consensus estimate of $3.94 billion. Throughout the identical quarter within the earlier yr, the agency posted $0.60 EPS. The agency’s quarterly income was down 7.3% on a year-over-year foundation. Analysts forecast that Teva Pharmaceutical Industries will put up 2.Four earnings per share for the present fiscal yr.
In associated information, Director Rosemary A. Crane bought 2,860 shares of the enterprise’s stock in a transaction dated Tuesday, August 11th. The shares have been bought at a median price of $11.90, for a complete transaction of $34,034.00. Following the completion of the sale, the director now owns 36,369 shares of the corporate’s stock, valued at roughly $432,791.10. The sale was disclosed in a authorized submitting with the SEC, which is accessible via this hyperlink. 0.56% of the stock is owned by company insiders.
A lot of institutional buyers have just lately purchased and bought shares of the enterprise. HighMark Wealth Administration LLC boosted its stake in Teva Pharmaceutical Industries by 64.6% through the 2nd quarter. HighMark Wealth Administration LLC now owns 2,155 shares of the corporate’s stock valued at $27,00Zero after buying a further 846 shares through the interval. Federated Hermes Inc. boosted its stake in Teva Pharmaceutical Industries by 89.2% through the 2nd quarter. Federated Hermes Inc. now owns 2,038 shares of the corporate’s stock valued at $25,00Zero after buying a further 961 shares through the interval. Johnson Funding Counsel Inc. boosted its stake in Teva Pharmaceutical Industries by 4.1% through the 2nd quarter. Johnson Funding Counsel Inc. now owns 30,914 shares of the corporate’s stock valued at $381,00Zero after buying a further 1,222 shares through the interval. Nwam LLC boosted its stake in Teva Pharmaceutical Industries by 4.6% through the 2nd quarter. Nwam LLC now owns 28,698 shares of the corporate’s stock valued at $354,00Zero after buying a further 1,254 shares through the interval. Lastly, AGF Investments America Inc. boosted its stake in Teva Pharmaceutical Industries by 1.4% through the 1st quarter. AGF Investments America Inc. now owns 95,946 shares of the corporate’s stock valued at $862,00Zero after buying a further 1,370 shares through the interval. 48.75% of the stock is owned by hedge funds and different institutional buyers.
Teva Pharmaceutical Industries Firm Profile
Teva Pharmaceutical Industries Restricted, a pharmaceutical firm, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates via two segments, Generic Medicines and Specialty Medicines. The Generic Medicines phase provides sterile merchandise, hormones, narcotics, high-potency medication, and cytotoxic substances in numerous dosage types, together with tablets, capsules, injectables, inhalants, liquids, ointments, and lotions.
Learn Extra: Price of Capital
This on the spot information alert was generated by narrative science know-how and monetary information from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to [email protected]